Muscle quantitative MRI as a novel biomarker in hereditary transthyretin amyloidosis with polyneuropathy: a cross-sectional study

[1]  N. Bergsland,et al.  Deep learning for automatic segmentation of thigh and leg muscles , 2021, Magnetic Resonance Materials in Physics, Biology and Medicine.

[2]  M. Froeling,et al.  3D Automated Segmentation of Lower Leg Muscles Using Machine Learning on a Heterogeneous Dataset , 2021, Diagnostics.

[3]  N. Bergsland,et al.  Reproducibility of manual segmentation in muscle imaging , 2021, Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology.

[4]  M. Maitland,et al.  CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis. , 2021, The New England journal of medicine.

[5]  Oliver Bieri,et al.  Fast Open-Source Toolkit for Water T2 Mapping in the Presence of Fat From Multi-Echo Spin-Echo Acquisitions for Muscle MRI , 2021, Frontiers in Neurology.

[6]  S. Heiland,et al.  Magnetization transfer ratio quantifies polyneuropathy in hereditary transthyretin amyloidosis , 2020, Annals of clinical and translational neurology.

[7]  R. Finkel,et al.  Modeling disease trajectory in Duchenne muscular dystrophy , 2020, Neurology.

[8]  Augustin C. Ogier,et al.  Fat fraction distribution in lower limb muscles of patients with CMT1A , 2020, Neurology.

[9]  P. Dyck,et al.  Transthyretin amyloidosis: Putting myopathy on the map , 2020, Muscle & nerve.

[10]  Hakmook Kang,et al.  Length‐dependent MRI of hereditary neuropathy with liability to pressure palsies , 2019, Annals of clinical and translational neurology.

[11]  I. Wilkinson,et al.  Longitudinal multi-modal muscle-based biomarker assessment in motor neuron disease , 2019, Journal of Neurology.

[12]  W. Litchy,et al.  Development of measures of polyneuropathy impairment in hATTR amyloidosis: From NIS to mNIS + 7 , 2019, Journal of the Neurological Sciences.

[13]  T. Hornemann,et al.  Development of MRC Centre MRI calf muscle fat fraction protocol as a sensitive outcome measure in Hereditary Sensory Neuropathy Type 1 , 2019, Journal of Neurology, Neurosurgery, and Psychiatry.

[14]  A. Pichiecchio,et al.  Advances in Quantitative Imaging of Genetic and Acquired Myopathies: Clinical Applications and Perspectives , 2019, Front. Neurol..

[15]  L. Greensmith,et al.  Skeletal muscle MRI differentiates SBMA and ALS and correlates with disease severity , 2018, Neurology.

[16]  M. de Carvalho,et al.  Natural history and survival in stage 1 Val30Met transthyretin familial amyloid polyneuropathy , 2018, Neurology.

[17]  S. Solomon,et al.  Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis , 2018, The New England journal of medicine.

[18]  S. Solomon,et al.  Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis , 2018, The New England journal of medicine.

[19]  G. Fink,et al.  MRI biomarkers of proximal nerve injury in CIDP , 2017, Annals of clinical and translational neurology.

[20]  S. Ayache,et al.  Assessing mNIS+7Ionis and international neurologists' proficiency in a familial amyloidotic polyneuropathy trial , 2017, Muscle & nerve.

[21]  W. Litchy,et al.  Trial design and rationale for APOLLO, a Phase 3, placebo-controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy , 2017, BMC Neurology.

[22]  S. Heiland,et al.  Sural nerve injury in familial amyloid polyneuropathy , 2017, Neurology.

[23]  S. Friedman,et al.  Quantitative MRI reveals decelerated fatty infiltration in muscles of active FSHD patients , 2016, Neurology.

[24]  H. Reyngoudt,et al.  Simultaneous muscle water T2 and fat fraction mapping using transverse relaxometry with stimulated echo compensation , 2016, NMR in biomedicine.

[25]  M. Russo,et al.  Monitoring effectiveness and safety of Tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic area , 2016, Journal of Neurology.

[26]  T. Yousry,et al.  MRI biomarker assessment of neuromuscular disease progression: a prospective observational cohort study , 2016, The Lancet Neurology.

[27]  B. Bettencourt,et al.  Rapid progression of familial amyloidotic polyneuropathy , 2015, Neurology.

[28]  Matthias Weigel,et al.  Extended phase graphs: Dephasing, RF pulses, and echoes ‐ pure and simple , 2015, Journal of magnetic resonance imaging : JMRI.

[29]  S. Heiland,et al.  In vivo detection of nerve injury in familial amyloid polyneuropathy by magnetic resonance neurography , 2014, Brain : a journal of neurology.

[30]  B. Bettencourt,et al.  Retrospective study of a TTR FAP cohort to modify NIS+7 for therapeutic trials , 2014, Journal of the Neurological Sciences.

[31]  E. Nordh,et al.  Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. , 2013, JAMA.

[32]  I. Merkies.  Tafamidis for transthyretin familial amyloid polyneuropathy: A randomized, controlled trial , 2013, Neurology.

[33]  J. Albers,et al.  "Unequivocally Abnormal" vs "Usual" Signs and Symptoms for Proficient Diagnosis of Diabetic Polyneuropathy: Cl vs N Phys Trial. , 2012, Archives of neurology.

[34]  Joel Kullberg,et al.  Three‐dimensional water/fat separation and T  2* estimation based on whole‐image optimization—Application in breathhold liver imaging at 1.5 T , 2012, Magnetic resonance in medicine.

[35]  O. Bieri,et al.  Quantitative MRI can detect subclinical disease progression in muscular dystrophy , 2012, Journal of Neurology.

[36]  G. Sobue,et al.  Natural history of transthyretin Val30Met familial amyloid polyneuropathy: analysis of late-onset cases from non-endemic areas , 2012, Journal of Neurology, Neurosurgery & Psychiatry.

[37]  W. Litchy,et al.  Signs and symptoms versus nerve conduction studies to diagnose diabetic sensorimotor polyneuropathy: Cl vs. NPhys trial , 2010, Muscle & nerve.

[38]  Y. Ando,et al.  Liver Transplantation for Familial Amyloidotic Polyneuropathy (FAP): A Single‐Center Experience Over 16 Years , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[39]  G. Sobue,et al.  Pathology of early- vs late-onset TTR Met30 familial amyloid polyneuropathy , 2004, Neurology.

[40]  C. Lacroix,et al.  Genotypic-phenotypic variations in a series of 65 patients with familial amyloid polyneuropathy , 1998, Neurology.

[41]  W. Litchy,et al.  Longitudinal assessment of diabetic polyneuropathy using a composite score in the Rochester Diabetic Neuropathy Study cohort , 1997, Neurology.

[42]  P. Dyck,et al.  The natural history of peripheral neuropathy in primary systemic amyloidosis , 1979, Annals of neurology.

[43]  X. Deligianni,et al.  Intra-rater and Inter-rater Reliability of Quantitative Thigh Muscle Magnetic Resonance Imaging , 2019 .